{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:17:20Z","timestamp":1790162240069,"version":"4.1.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia (ATL) consists of an overabundance of T cells, which express CD25. Therapeutic efficacy of astatine-211 (211At)\u2013labeled murine monoclonal antibody 7G7\/B6 alone and in combination with daclizumab was evaluated in nonobese diabetic\/severe combined immunodeficiency (NOD\/SCID) mice given injections of MET-1 human T-cell leukemia cells. Daclizumab and 7G7\/B6 are directed toward different epitopes of CD25. Either a single dose of 12 \u03bcCi (0.444 MBq) 211At-7G7\/B6 per mouse given intravenously or receptor-saturating doses of daclizumab given at 100 \u03bcg weekly for 4 weeks intravenously inhibited tumor growth as monitored by serum levels of human \u03b2-2 microglobulin (\u03b22\u03bc) and by prolonged survival of leukemia-bearing mice compared with the control groups (P &lt; .001). The combination of 2 agents enhanced the antitumor effect when compared with groups treated with 12 \u03bcCi (0.444 MBq) of 211At-7G7\/B6 (P &lt; .05) or daclizumab alone (P &lt; .05). The median survival duration of the PBS group was 62.6 days and 61.5 days in the radiolabeled nonspecific antibody 211At-11F11\u2013treated group. In contrast, 91% of mice in the combination group survived through day 94. These results that demonstrate a significantly improved therapeutic efficacy by combining 211At-7G7\/B6 with daclizumab support a clinical trial of this regimen in patients with ATL.<\/jats:p>","DOI":"10.1182\/blood-2005-11-4757","type":"journal-article","created":{"date-parts":[[2006,3,29]],"date-time":"2006-03-29T04:38:48Z","timestamp":1143607128000},"page":"1007-1012","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Effective treatment of a murine model of adult T-cell leukemia using 211At-7G7\/B6 and its combination with unmodified anti-Tac (daclizumab) directed toward CD25"],"prefix":"10.1182","volume":"108","author":[{"given":"Zhuo","family":"Zhang","sequence":"first","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayhan","family":"Garmestani","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir S.","family":"Talanov","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Plascjak","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Beck","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Goldman","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Brechbiel","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Waldmann","sequence":"additional","affiliation":[{"name":"From the Metabolism Branch and the Radiation Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD; and Clinical Center, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712055017300_REF1","doi-asserted-by":"crossref","unstructured":"Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia\/lymphoma: a report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991;79: 428-437.","DOI":"10.1111\/j.1365-2141.1991.tb08051.x"},{"key":"2019111712055017300_REF2","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Broder S, Waldmann TA. A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T cells, I: production of anti-Tac monoclonal antibody and distribution of Tac (+) cells. J Immunol. 1981;126: 1393-1397.","DOI":"10.4049\/jimmunol.126.4.1393"},{"key":"2019111712055017300_REF3","doi-asserted-by":"crossref","unstructured":"Waldmann TA, Greene WC, Sarin PS, et al. Functional and phenotypic comparison of human T cell leukemia\/lymphoma virus positive adult T cell leukemia with human T cell leukemia\/lymphoma virus negative Sezary leukemia, and their distinction using anti-Tac: monoclonal antibody identifying the human receptor for T cell growth factor. J Clin Invest. 1984;73: 1711-1718.","DOI":"10.1172\/JCI111379"},{"key":"2019111712055017300_REF4","doi-asserted-by":"crossref","unstructured":"Uchiyama T, Hori T, Tsudo M, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J Clin Invest. 1985;76: 446-453.","DOI":"10.1172\/JCI111992"},{"issue":"suppl 1","key":"2019111712055017300_REF5","first-page":"i109","volume":"59","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"2019111712055017300_REF6","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82: 1701-1712.","DOI":"10.1182\/blood.V82.6.1701.1701"},{"key":"2019111712055017300_REF7","doi-asserted-by":"crossref","unstructured":"Waldmann TA, White JD, Carrasquillo JA, et al. Radioimmunotherapy of interleukin-2R alpha-expressing adult T-cell leukemia with yttrium-90-labeled anti-Tac. Blood. 1995;86: 4063-4075.","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"key":"2019111712055017300_REF8","unstructured":"Phillips KE, Herring B, Wilson LA, et al. IL-2Ralpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2Ralpha interaction. Cancer Res. 2000;60: 6977-6984."},{"key":"2019111712055017300_REF9","doi-asserted-by":"crossref","unstructured":"Zhang M, Yao Z, Garmestani K, et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood. 2002;100: 208-216.","DOI":"10.1182\/blood-2002-01-0107"},{"key":"2019111712055017300_REF10","doi-asserted-by":"crossref","unstructured":"Zhang M, Zhang Z, Garmestani K, et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia\/lymphoma xenografts. Proc Natl Acad Sci U S A. 2003;100: 1891-1895.","DOI":"10.1073\/pnas.0437788100"},{"key":"2019111712055017300_REF11","doi-asserted-by":"crossref","unstructured":"Zhang Z, Zhang M, Ravetch JV, Goldman C, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102: 284-288.","DOI":"10.1182\/blood-2002-11-3601"},{"key":"2019111712055017300_REF12","unstructured":"Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H. Cancer Res. 2003;63: 6453-6457."},{"key":"2019111712055017300_REF13","unstructured":"Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 2002;62: 1083-1086."},{"key":"2019111712055017300_REF14","doi-asserted-by":"crossref","unstructured":"Zhang M, Zhang Z, Goldman CK, Janik J, Waldmann TA. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood. 2005;105: 1231-1236.","DOI":"10.1182\/blood-2004-05-1709"},{"key":"2019111712055017300_REF15","doi-asserted-by":"crossref","unstructured":"Wilder RB, DeNardo GL, DeNardo SJ. Radioimmunotherapy: recent results and future directions. Clin Oncol. 1996;4: 1383-1400.","DOI":"10.1200\/JCO.1996.14.4.1383"},{"key":"2019111712055017300_REF16","doi-asserted-by":"crossref","unstructured":"Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352: 441-449.","DOI":"10.1056\/NEJMoa041511"},{"key":"2019111712055017300_REF17","unstructured":"Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2: 457-470."},{"key":"2019111712055017300_REF18","doi-asserted-by":"crossref","unstructured":"Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346: 336-440.","DOI":"10.1016\/S0140-6736(95)92225-3"},{"key":"2019111712055017300_REF19","unstructured":"Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted {alpha}-particle therapy. J Nucl Med. 2005;46: 199S-204S."},{"key":"2019111712055017300_REF20","doi-asserted-by":"crossref","unstructured":"Brown I. Astatine-211: its possible applications in cancer therapy. Int J Rad Appl Instrum [A]. 1986;37: 789-798.","DOI":"10.1016\/0883-2889(86)90273-X"},{"key":"2019111712055017300_REF21","doi-asserted-by":"crossref","unstructured":"Macklis RM, Kinsey BM, Kassis AI, et al. Radio-immunotherapy with alpha-particle-emitting immunoconjugates. Science. 1988;240: 1024-1026.","DOI":"10.1126\/science.2897133"},{"key":"2019111712055017300_REF22","doi-asserted-by":"crossref","unstructured":"Macklis RM, Kaplan WD, Ferrara JL, et al. Alpha particle radio-immunotherapy: animal models and clinical prospects. Int J Radiat Oncol Biol Phys. 1989;16: 1377-1387.","DOI":"10.1016\/0360-3016(89)90938-3"},{"key":"2019111712055017300_REF23","doi-asserted-by":"crossref","unstructured":"Vaidyanathan G, Zalutsky MR. Targeted therapy using alpha emitters. Phys Med Biol. 1996;41: 1915-1931.","DOI":"10.1088\/0031-9155\/41\/10\/005"},{"key":"2019111712055017300_REF24","doi-asserted-by":"crossref","unstructured":"Rubin LA, Kurman CC, Biddison WE, Goldman ND, Nelson DL. A monoclonal antibody 7G7\/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma. 1985;4: 91-102.","DOI":"10.1089\/hyb.1985.4.91"},{"key":"2019111712055017300_REF25","doi-asserted-by":"crossref","unstructured":"Press OW, Corcoran M, Subbiah K, et al. A comparative evaluation of conventional and pretargeted radioimmunotherapy of CD20-expressing lymphoma xenografts. Blood. 2001;98: 2535-2543.","DOI":"10.1182\/blood.V98.8.2535"},{"key":"2019111712055017300_REF26","doi-asserted-by":"crossref","unstructured":"Perera LP, Marques LR, O'Brien AD. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohememarragic Escherichia and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol. 1988;26: 2127-2131.","DOI":"10.1128\/JCM.26.10.2127-2131.1988"},{"key":"2019111712055017300_REF27","doi-asserted-by":"crossref","unstructured":"Schwarz UP, Plascjak P, Beitzel MP, et al. Preparation of 211At-labeled humanized anti-Tac using 211At produced in disposable internal and external bismuth targets. Nucl Med Biol. 1998;25: 89-93.","DOI":"10.1016\/S0969-8051(97)00165-0"},{"key":"2019111712055017300_REF28","doi-asserted-by":"crossref","unstructured":"Yordanov AT, Garmestani K, Zhang M, et al. Preparation and in vivo evaluation of linkers for 211At labeling of humanized anti-Tac. Nucl Med Biol. 2001;28: 845-856.","DOI":"10.1016\/S0969-8051(01)00257-8"},{"key":"2019111712055017300_REF29","doi-asserted-by":"crossref","unstructured":"Kozak RW, Waldmann TA, Atcher RW, Gansow OA. Radionuclide-conjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science. Trends Biotechnol1985;4: 259-264.","DOI":"10.1016\/0167-7799(86)90189-7"},{"key":"2019111712055017300_REF30","unstructured":"Zalutsky MR, Pozzi OR. Radioimmunotherapy with alpha-particle emitting radionuclides. Q J Nucl Med Mol Imaging. 2004;48: 289-296."},{"key":"2019111712055017300_REF31","doi-asserted-by":"crossref","unstructured":"Wesley JN, McGee EC, Garmestani K, et al. Systemic radioimmunotherapy using a monoclonal antibody, anti-Tac directed toward the alpha subunit of the IL-2 receptor armed with the alpha-emitting radionuclides (212)Bi or (211)At. Nucl Med Biol. 2004;31: 357-364.","DOI":"10.1016\/j.nucmedbio.2003.08.011"},{"key":"2019111712055017300_REF32","unstructured":"Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2\/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58: 2825-2831."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/1007\/1282819\/zh801506001007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/108\/3\/1007\/1282819\/zh801506001007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T21:52:10Z","timestamp":1683409930000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/108\/3\/1007\/22374\/Effective-treatment-of-a-murine-model-of-adult"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,8,1]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-11-4757","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,8,1]]}}}